Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience

Helena Gama,Mariana Vieira,Raquel Costa,Joana Graça,Luís M. Magalhães,Patrício Soares-da-Silva

Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience

2017

Helena Gama
Mariana Vieira
Raquel Costa
Joana Graça
Luís M. Magalhães
Patrício Soares-da-Silva

Introduction Eslicarbazepine acetate was first approved in the European Union in 2009 as adjunctive therapy in adults with partial-onset seizures with or without secondary generalization.

Keywords:

Refractory
Medicine
Pharmacology
Diabetes mellitus
Secondary generalization
Eslicarbazepine acetate
European union
Adverse drug reaction
Discontinuation
Adverse effect
Nausea
Rash
Hyponatremia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations